Head-to-head evidence
CX11 vs VCT220
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
CX11
Developed by Corxel Pharmaceuticals
NCT07011797 · Phase 2 · completed
In this randomized, double-blind, placebo-controlled Phase 2 trial, 250 adults with obesity were assigned to CX11 at several doses or placebo for 26 weeks, with follow-up to 36 weeks. The company reported that the trial's weight-loss primary endpoints were met, with weight loss reaching up to 11.5% by week 36 and continuing without a plateau; gastrointestinal side effects were the most common safety finding.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT07652047 (registry estimate)
VCT220
Developed by Ji Xing Pharmaceuticals (CORXEL) under a licence from Vincentage Pharma
NCT06569355 · Phase 2 · completed
This Phase 2 trial randomly assigned 250 people with obesity or overweight to one of several VCT220 doses or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was percentage change in body weight at week 16. Weight fell by between 5.8% and 9.7% across the VCT220 dose groups against 1.6% on placebo, with reductions of 9.7% and 9.4% at the two 160 mg schedules (p of 0.001 or lower).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CX11's landscape · VCT220's landscape